Highlights

  • Cogstate Ltd (ASX:CGS) shares closed at AUD 2.930 on 19 August 2026, increasing 7.326% during the session.
  • FY26 Revenue increased 15% to AUD 60.9 million, with net profit after tax rising 17% to AUD 11.9 million.
  • Contracted future revenue increased 32% to US$118.5 million.
  • Clinical trial activity expanded to 171 ongoing trials during FY26.
  • The company plans a two-year Investment program focused on AI-enabled clinical trial capabilities.

Cogstate Ltd (ASX:CGS) shares closed at AUD 2.930 on 19 August 2026, increasing AUD 0.200 or 7.326% compared with the previous close of AUD 2.730. The stock traded between AUD 2.690 and AUD 2.950, with a Volume of 1,551,820 shares.

The company recorded a Market Capitalisation of AUD 463.87 million, with 169,919,352 ordinary fully paid shares on issue.

The share price movement followed the release of Cogstate’s FY26 results, which highlighted growth in revenue, profitability, clinical trial activity and future contracted revenue.

Business Overview and Healthcare Technology Operations

Cogstate provides computerised cognitive assessments used in clinical trials, particularly for central nervous system (CNS) treatments. Its technology helps pharmaceutical companies measure cognitive performance during Drug Development programs.

The company operates mainly through its Clinical Trials business, with a smaller healthcare segment focused on cognitive screening applications.

Cogstate’s assessments are designed for use across international clinical trials, supporting research in areas including Alzheimer’s disease, mood disorders, sleep disorders and other neurological conditions.

FY26 Financial Performance

For FY26, Cogstate reported revenue of AUD 60.9 million, increasing 15% compared with the previous year.

Gross profit increased to AUD 35.4 million, with a gross Margin of 58%. Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) was AUD 18.3 million, representing a 30% margin.

Profit before tax increased 16% to AUD 16.1 million, while Net Profit After Tax (NPAT) increased 17% to AUD 11.9 million.

The company ended FY26 with AUD 34.8 million in cash and no debt. Cogstate also increased its Dividend to AUD 0.04 per share, alongside continuing share buy-back activities.

Contract Growth and Clinical Trial Activity

A key focus from the FY26 update was growth in future contracted revenue.

Cogstate reported contracted future revenue of US$118.5 million, increasing 32% year-on-year. Of this amount, approximately US$48.3 million is expected to be recognised during FY27.

The company also reported FY26 net new sales contracts of US$89.0 million, more than double the US$41.3 million recorded in FY25.

Operational activity also expanded, with 171 ongoing clinical trials at year-end compared with 110 previously. The company reported 90 new trial starts during FY26, compared with 35 in FY25.

The therapeutic mix has also broadened, with activity across mood, sleep, neurology, rare diseases and Alzheimer’s disease programs.

AI Investment Program and Future Strategy

Cogstate announced a two-year investment program across FY27 and FY28 focused on developing an AI-enabled operating platform for CNS clinical trials.

The program is designed to support future clinical trial capabilities and operational improvements. However, the investment will increase costs before potential benefits are realised.

The company’s future performance will depend on converting its contract pipeline into recognised revenue while managing investment requirements.

Key Areas to Monitor

Investors will monitor the conversion of contracted future revenue into reported revenue, particularly the US$48.3 million expected during FY27.

Revenue timing has previously influenced market expectations, making contract execution and recognition schedules important factors.

Other areas of focus include clinical trial growth, AI investment progress, gross margins and the company’s ability to maintain profitability while investing in future capabilities.

Risks and Challenges

Cogstate faces risks related to clinical trial timing, customer concentration, investment execution, currency movements and healthcare research cycles.

The company’s revenue depends on pharmaceutical and biotechnology trial activity, which can change due to funding decisions and trial timelines. The AI investment program also carries execution risks, as benefits may take time to develop.

Revenue is largely generated in US dollars while reporting is presented in Australian dollars, creating foreign exchange exposure.

Outlook

Cogstate enters FY27 with a larger contracted revenue base, expanded clinical trial activity and continued investment in technology capabilities. The company expects gross margins of 58–60% and EBITDA margins around 30%, while future results will depend on contract conversion and successful execution of its AI-enabled platform strategy.

Conclusion

Cogstate’s share price movement on 19 August 2026 followed FY26 results that highlighted higher revenue, improved profitability and increased contracted future revenue. The company continues expanding its clinical trial technology platform while investing in AI capabilities. However, revenue timing, customer concentration and execution of future investments remain important factors as the company progresses through FY27.